CN112980846B - 一种Pax2条件性基因敲除小鼠模型的构建方法 - Google Patents
一种Pax2条件性基因敲除小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN112980846B CN112980846B CN202110381604.5A CN202110381604A CN112980846B CN 112980846 B CN112980846 B CN 112980846B CN 202110381604 A CN202110381604 A CN 202110381604A CN 112980846 B CN112980846 B CN 112980846B
- Authority
- CN
- China
- Prior art keywords
- pax2
- seq
- mice
- nucleotide sequence
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 title claims abstract description 44
- 238000003209 gene knockout Methods 0.000 title claims abstract description 29
- 238000010276 construction Methods 0.000 title claims abstract description 26
- 238000010172 mouse model Methods 0.000 title claims abstract description 25
- 241000699670 Mus sp. Species 0.000 claims abstract description 70
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 42
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 239000013612 plasmid Substances 0.000 claims abstract description 18
- 230000008685 targeting Effects 0.000 claims abstract description 18
- 108091033409 CRISPR Proteins 0.000 claims abstract description 17
- 238000012216 screening Methods 0.000 claims abstract description 15
- 108020004414 DNA Proteins 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 238000000137 annealing Methods 0.000 claims description 24
- 238000003776 cleavage reaction Methods 0.000 claims description 19
- 230000007017 scission Effects 0.000 claims description 19
- 238000004925 denaturation Methods 0.000 claims description 16
- 230000036425 denaturation Effects 0.000 claims description 16
- 238000010367 cloning Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 230000013011 mating Effects 0.000 claims description 8
- 238000012257 pre-denaturation Methods 0.000 claims description 8
- 238000000520 microinjection Methods 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 210000004681 ovum Anatomy 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 abstract description 10
- 235000013601 eggs Nutrition 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 238000009396 hybridization Methods 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000011814 C57BL/6N mouse Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种Pax2条件性基因敲除小鼠模型的构建方法,涉及动物模型构建技术领域。本发明所述sgRNAs分别设计在Pax2基因的intron1和intron2非保守区中,5'端和3'端的同源臂分别约为1.4kb和1.4kb。本发明基于上述sgRNA设计了Pax2条件性基因敲除小鼠模型的构建方法,将Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,通过两步筛选和一次杂交,获得Pax2条件性基因敲除小鼠模型,运用cre‑loxp系统,构建出flox小鼠后可与不同的cre工具鼠灵活搭配运用,研究目的基因在不同组织器官,甚至不同细胞类型中的作用机制。
Description
技术领域
本发明属于动物模型构建技术领域,具体涉及一种Pax2条件性基因敲除小鼠模型的构建方法。
背景技术
Pax为全长配对盒基因,属于发育调控基因家族,在胚胎发育过程中,可通过编码核转录因子,达到促进组织增生、抑制细胞凋亡和协调细胞的特殊分化的作用。近年来发现与核转录因子有关的Pax家族中的Pax2在免疫组织化学中具有明显的应用,如Pax2同源基因在肾脏的分化过程中表现出强表达,特别是后肾间叶细胞,是间叶细胞向上皮细胞转化的关键因素;同时关于Pax2基因的致瘤性在体外和裸鼠体内试验中也有报道,Pax2在体外肾癌的细胞株上表达,在卵巢浆液性乳头状瘤中也有较高表达。但是目前关于Pax2的作用机理并不深刻,且也没有相关的动物模型进行相关的研究。
发明内容
有鉴于此,本发明的目的在于提供一种靶向小鼠Pax2基因的sgRNA及Pax2条件性基因敲除模型的构建方法,可成功构建Pax2条件性基因敲除小鼠模型,运用cre-loxp系统,构建出flox小鼠后可与不同的cre工具鼠灵活搭配运用,研究目的基因在不同组织器官,甚至不同细胞类型中的作用机制,为国内外提供有效的模型动物。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种靶向小鼠Pax2基因的sgRNA,所述sgRNA包括5’Guide序列和3’Guide序列,所述5’Guide包括SEQ ID NO.1~SEQ ID NO.8所示的任意一条序列;所述3’Guide序列包括SEQ ID NO.9~SEQ ID NO.16所示的任意一条序列。
优选的,所述sgRNA的5’Guide序列如SEQ ID NO.5所示,且所述sgRNA的3’Guide序列如SEQ ID NO.10所示。
优选的,所述小鼠Pax2基因在NCBI的Gene ID为18504。
本发明提供了一种Pax2条件性基因敲除小鼠模型的构建方法,包括以下步骤:(1)以小鼠基因组DNA为模板,分别克隆小鼠Pax2基因的LR、A和RR片段,依次将所述LR、A和RR片段连接至LScKO-2G载体,得特异性打靶载体;克隆所述LR片段的引物包括Pax2-LR-F和Pax2-LR-R,其中所述Pax2-LR-F的核苷酸序列如SEQ ID NO.17所示,所述Pax2-LR-R的核苷酸序列如SEQ ID NO.18所示;克隆所述A片段的引物包括Pax2-A-F和Pax2-A-R,所述Pax2-A-F的核苷酸序列如SEQ ID NO.19所示,所述Pax2-A-R的核苷酸序列如SEQ ID NO.20所示;克隆所述RR片段的引物包括Pax2-RR-F和Pax2-RR-R,所述Pax2-RR-F的核苷酸序列如SEQID NO.21所述,所述Pax2-RR-R的核苷酸序列如SEQ ID NO.22所示;
(2)将上述sgRNA合成oligos,连接入pUC载体,得Cas9/sgRNA质粒;
(3)将Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,出生后得F0代小鼠;
(4)筛选F0代小鼠中基因重组正确的个体与野生型小鼠交配得到F1代小鼠;
(5)筛选所述F1代小鼠中基因正确表达的杂合子小鼠与组织特异性的Cre小鼠交配,得所述Pax2条件性基因敲除小鼠模型;
步骤(1)和(2)之间不存在时间上的先后关系。
优选的,步骤(1)中扩增所述LR、A和RR片段的PCR程序,均为:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
优选的,步骤(1)所述连接包括依次将LR片段连接至Not I和BamH I酶切位点之间,将A片段连接至Sal I和Bgl II酶切位点之间,将RR片段连接至Xho I和EcoR I酶切位点之间。
优选的,步骤(4)所述筛选包括利用两对引物进行PCR,其中一对包括Pax2-L-GT-F和cKO-5'-DO-F;另一对包括cKO-3'-DO-R和Pax2-R-GT-R;
所述Pax2-L-GT-F的核苷酸序列如SEQ ID NO.23所示,所述cKO-5'-DO-F的核苷酸序列如SEQ ID NO.24所示;
所述cKO-3'-DO-R的核苷酸序列如SEQ ID NO.25所示,所述Pax2-R-GT-R的核苷酸序列如SEQ ID NO.26所示。
优选的,步骤(5)所述筛选包括利用两对引物进行PCR,其中一对引物包括Pax2-L-GT-F2和cKO-5'-DO-F;另一对引物包括cKO-3'-DO-R和Pax2-R-GT-R1;所述Pax2-L-GT-F2的核苷酸序列如SEQ ID NO.27所示,所述Pax2-R-GT-R1的核苷酸序列如SEQ ID NO.28所示。
优选的,步骤(4)和步骤(5)所述筛选时,PCR扩增的程序均包括:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
本发明还提供了利用上述构建方法构建得到的Pax2条件性基因敲除小鼠模型在构建全身性基因敲除小鼠模型中的应用。
本发明提供了一种靶向小鼠Pax2基因的sgRNA,sgRNAs分别设计在Pax2(也称EGE-YHN-011-A,在19号染色体反链上,全长91.7kb,Gene ID:18504)基因的intron1和intron2非保守区中,5'端和3'端的同源臂分别约为1.4kb和1.4kb。
本发明基于上述sgRNA设计了Pax2条件性基因敲除小鼠模型的构建方法,将Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,通过两步筛选和一次杂交,获得Pax2条件性基因敲除小鼠模型,运用cre-loxp系统,构建出flox小鼠后可与不同的cre工具鼠灵活搭配运用,研究目的基因在不同组织器官,甚至不同细胞类型中的作用机制,为国内外提供有效的模型动物。
附图说明
图1为特异性打靶载体的质粒图谱;
图2为本发明构建的Cas9/sgRNA质粒图谱;
图3为F0代小鼠基因型鉴定的引物设计原则;
图4为F1代小鼠基因型鉴定的引物设计原则;
图5为F1代杂合子小鼠与组织特异性的Cre小鼠交配方案;
图6为获得全身性基因敲除的小鼠的交配方案;
图7为sgRNA的活性检测结果;
图8为F0代小鼠基因型鉴定结果;
图9为F1代小鼠基因型鉴定结果;
图10为F1代PCR阳性小鼠Southernblot检测结果。
具体实施方式
本发明提供了一种靶向小鼠Pax2基因的sgRNA,所述sgRNA包括5’Guide序列和3’Guide序列,所述5’Guide包括SEQ ID NO.1~SEQ ID NO.8所示的任意一条序列;所述3’Guide序列包括SEQ ID NO.9~SEQ ID NO.16所示的任意一条序列。
本发明所述小鼠Pax2基因(实施例部分图片中也称EGE-YHN-011-A)在NCBI的GeneID为18504,包含3个转录本:Pax2-201(ENSMUST00000174490.8)、Pax2-202(ENSMUST00000173346.3)和Pax2-203(ENSMUST00000004340.10),本申请实施例中优选以Pax2-203为基础进行sgRNA的设计,所设计的sgRNA序列如表1和表2所示。
表15’Guide序列信息
5’Guide | 序列(5’-3’) | SEQIDNO |
Guide#1 | ACCCGCCTGCGCCGCAGGTTTGG | 1 |
Guide#2 | CGCCAAACCTGCGGCGCAGGCGG | 2 |
Guide#3 | CCGCGCCAAACCTGCGGCGCAGG | 3 |
Guide#4 | TAGAAACCCGCCTGCGCCGCAGG | 4 |
Guide#5 | CTCAAGCCGCGCCAAACCTGCGG | 5 |
Guide#6 | AGTTAGGCAGCGAAGGTGAACGG | 6 |
Guide#7 | AAGGGGAAATAATGTTAACGGGG | 7 |
Guide#8 | GAAGGTGAACGGGATGTGTTTGG | 8 |
表23’Guide序列信息
本发明优选对Guide#5和Guide#10进行功能验证和后续小鼠模型的构建。
本发明提供了一种Pax2条件性基因敲除小鼠模型的构建方法,包括以下步骤:(1)以小鼠基因组DNA为模板,分别克隆小鼠Pax2基因的LR、A和RR片段,依次将所述LR、A和RR片段连接至LScKO-2G载体,得特异性打靶载体;克隆所述LR片段的引物包括Pax2-LR-F和Pax2-LR-R,其中所述Pax2-LR-F的核苷酸序列如SEQ ID NO.17所示,所述Pax2-LR-R的核苷酸序列如SEQ ID NO.18所示;克隆所述A片段的引物包括Pax2-A-F和Pax2-A-R,所述Pax2-A-F的核苷酸序列如SEQ ID NO.19所示,所述Pax2-A-R的核苷酸序列如SEQ ID NO.20所示;克隆所述RR片段的引物包括Pax2-RR-F和Pax2-RR-R,所述Pax2-RR-F的核苷酸序列如SEQID NO.21所述,所述Pax2-RR-R的核苷酸序列如SEQ ID NO.22所示;
(2)将上述sgRNA合成oligos,连接入pUC载体,得Cas9/sgRNA质粒;
(3)将Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,出生后得F0代小鼠;
(4)筛选F0代小鼠中基因重组正确的个体与野生型小鼠交配得到F1代小鼠;
(5)筛选所述F1代小鼠中基因正确表达的杂合子小鼠与组织特异性的Cre小鼠交配,得所述Pax2条件性基因敲除小鼠模型;
步骤(1)和(2)之间不存在时间上的先后关系。
本发明以小鼠基因组DNA为模板,分别克隆小鼠Pax2基因的LR、A和RR片段,依次将所述LR、A和RR片段连接至LScKO-2G载体,得特异性打靶载体;克隆所述LR、A和RR片段的引物如表3所示,且在Pax2-LR-F的序列中添加Not I酶切位点,Pax2-LR-R的序列中添加BamHI酶切位点,Pax2-A-F的序列中添加Sal I酶切位点,Pax2-A-R的序列中添加Bgl II酶切位点,Pax2-RR-F的序列中添加Xho I酶切位点,Pax2-RR-R的序列中添加EcoR I酶切位点。
表3克隆LR、A和RR片段的引物信息
本发明利用表3中所述的引物和模板DNA进行相应的片段扩增,所述扩增的PCR体系以20μl计,优选均包括:ddH2O 1.9μl、2×KOD FX buffer 10μl、2mM dNTPs 4μl、10μMPrimer-F 0.6μl、10μMPrimer-R 0.6μl、DMSO1μl、1U/μl KOD FX DNAPolymerase 0.4μl、100~200ng/20μl Template DNA1.5μl;程序优选均为94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
本发明优选将测序正确后的上述扩增产物使用对应的限制性内切酶,依次将片段LR、A、RR连接至LScKO-2G载体,最终形成如图1所示的打靶载体。本发明对所述连接的方法并没有特殊限定,优选能够依次将LR片段连接至Not I和BamH I酶切位点之间,将A片段连接至Sal I和Bgl II酶切位点之间,将RR片段连接至Xho I和EcoR I酶切位点之间即可。本发明在得到所述打靶载体后,优选还包括进行酶切检测和质粒测序,其中酶切检测所用的限制性内切酶组合优选如表4所示。
表4酶切检测所用酶信息
组合序号 | 限制性内切酶 | 酶切片段(bp) |
1 | BglII+ScaI | 3231+2430+1084 |
2 | ScaI+EcoRI | 3522+1809+1414 |
3 | NcoI | 3671+2086+988 |
本发明将上述sgRNA合成oligos,连接入pUC载体,得Cas9/sgRNA质粒。本发明将sgRNA退火后合成所述oligos,然后通过Gibson的方式连入pUC载体,连接产物转化后送样测序验证正确,即可得如图2所示的Cas9/sgRNA质粒。本发明在利用所述Cas9/sgRNA质粒进行后续显微注射前,优选还包括对sgRNA进行活性检测,综合sgRNA活性值和特异性进行选择,最终利用Guide#5和Guide#10进行后续的模型构建。
得Cas9/sgRNA质粒和所述特异性打靶载体后,本发明将所述Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,出生后得F0代小鼠。在本发明中,由于受精卵注射方法得到F0代小鼠可能为嵌合体/杂合/纯合,所以在进行后续操作前,需要对F0代小鼠进行基因型鉴定,且鉴定得到的的基因型仅供参考。
得F0代小鼠后,本发明筛选F0代小鼠中基因重组正确的个体与野生型小鼠交配得到F1代小鼠。本发明优选根据如图3所示原则设计如表5所示的引物,并配置如上所述的PCR体系;PCR扩增的程序优选包括:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。筛选阳性和疑似阳性的F0代小鼠进行后续的杂交。本发明对所述杂交的亲本并没有特殊限定。
表5F0代小鼠基因型检测引物
得F1代小鼠后,本发明筛选所述F1代小鼠中基因正确表达的杂合子小鼠与组织特异性的Cre小鼠交配,得所述Pax2条件性基因敲除小鼠模型。本发明优选依据图4所示引物设计原则设计表6所示引物,并配置如上所述的PCR体系;PCR扩增的程序优选包括:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
表6F1代小鼠基因型检测引物
本发明在得到具有上述特征产物的阳性F1代小鼠后,优选还包括对所述阳性F1代小鼠的鼠尾DNA进行Southern blot检测及测序,本发明对所述Southern blot检测的方法并没有特殊限定。
本发明优选按照图5所示方案进行所述交配,且所述组织特异性的Cre小鼠优选购自美国jackson实验室。本发明得到的所述Pax2条件性基因敲除小鼠,均为杂合子,基因型为(fl/+,Cre/+),将其相互交配,可得到纯合子小鼠(fl/fl,Cre/+)。
本发明还提供了利用上述构建方法构建得到的Pax2条件性基因敲除小鼠模型在构建全身性基因敲除小鼠模型中的应用。本发明优选利用所述Pax2条件性基因敲除小鼠模型与Cre-deleter小鼠交配(图6),从而实现目的基因全身性的敲除。
下面结合实施例对本发明提供的一种Pax2条件性基因敲除小鼠模型的构建方法进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
1靶序列的测序确认
为了保证所设计Cas9/sgRNA的效率,首先对C57BL/6N鼠尾靶位点序列进行PCR扩增并测序验证(表7),以保证sgRNA识别序列与C57BL/6N鼠尾DNA序列完全一致。通过对C57BL/6N鼠尾DNA进行靶位点序列PCR及测序,结果证明:C57BL/6N鼠尾靶序列与Genebank和Ensembl所给序列完全一致。
表7PCR扩增用引物
PCR扩增体系:2×KOD FX buffer 10μl、2mM dNTPs 4μl、10μMPrimer-F 0.6μl、10μM Primer-R 0.6μl、DMSO 1μl、1U/L KOD FX DNA Polymerase 0.4μl、100-200ng/20lTemplate DNA 1.5μl、ddH2O 1.9μl;
PCR扩增程序:94℃预变性2min;98℃变性10s,67℃退火30s(-0.7℃/循环),68℃延伸1kg/min,15个循环;98℃变性10s,57℃退火30s,68℃延伸1kg/min,25个循环;68℃延伸10min;4℃保存。
2sgRNA的设计及Cas9/sgRNA质粒的构建
基于sgRNA的设计原则,在5'靶位点和3'靶位点区域分别设计如表1和表2所示的8条sgRNA,设计sgRNA序列合成oligos,通过Gibson的方式连入pUC载体,连接产物转化后送样测序验证正确(图2),对各sgRNA的活性进行检测(UCA CRISPR-Cas9快速构建及活性检测试剂盒),检测结果如表8和图7所示,综合选择EGE-YHN-011-A-sgRNA5(Guide#5)和EGE-YHN-011-A-sgRNA10(Guide#10)进行下一步实验。
表8各sgRNA的活性
3打靶载体的构建
使用表3中所示的引物分别扩增获得不同的PCR产物(片段LR、A、RR),测序正确后使用对应的限制性内切酶,依次将片段LR、A、RR连接至LScKO-2G载体,最终形成如图1所示的打靶载体,并进行酶切检测(酶切组合如表4所示)和质粒测序。
4受精卵显微注射
Cas9/sgRNA、打靶载体显微注射到小鼠受精卵中,注射后F0代小鼠出生情况如表9所示。
表9 F0代小鼠出生情况
5F0代小鼠基因型鉴定
根据表5所示引物对F0代小鼠进行基因型鉴定,结果如图8所示,E1N11-0013,E1N11-0032和E1N11-0042为F0代阳性小鼠,E1N11-0021和E1N11-0045为F0代疑似阳性小鼠。
6F1代小鼠基因型及Southernblot鉴定
选择上述部分F0代阳性小鼠与野生型小鼠交配得到F1代,交配结果如表10所示。
表10 F1代小鼠出生情况
7F1代小鼠基因型鉴定
根据表6所示引物进行PCR验证,结果如图9所示,1E1N11-0008,1E1N11-0009,1E1N11-0014,1E1N11-0016,1E1N11-0020,1E1N11-0022和1E1N11-0023为PCR阳性F1代小鼠。
8F1代PCR阳性小鼠Southern blot检测
提取上述PCR鉴定为阳性F1小鼠鼠尾DNA进行Southern blot检测及测序,检测结果表明:1E1N11-0008和1E1N11-0009(图10)均为正确重组,且没有随机插入。
9获得条件性基因敲除小鼠
将上述正确重组的F1代PCR阳性小鼠与组织特异性Cre小鼠(Ts-Cre)交配,获得floxed杂合子小鼠(Pax2条件性基因敲除小鼠,基因型为fl/+,Cre/+),并将其相互交配,得到纯合子小鼠(fl/fl,Cre/+)。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 山西省人民医院
<120> 一种Pax2条件性基因敲除小鼠模型的构建方法
<160> 32
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 1
acccgcctgc gccgcaggtt tgg 23
<210> 2
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 2
cgccaaacct gcggcgcagg cgg 23
<210> 3
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 3
ccgcgccaaa cctgcggcgc agg 23
<210> 4
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 4
tagaaacccg cctgcgccgc agg 23
<210> 5
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 5
ctcaagccgc gccaaacctg cgg 23
<210> 6
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 6
agttaggcag cgaaggtgaa cgg 23
<210> 7
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 7
aaggggaaat aatgttaacg ggg 23
<210> 8
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 8
gaaggtgaac gggatgtgtt tgg 23
<210> 9
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 9
tctacattga ttagctgggg ggg 23
<210> 10
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 10
ggaaggctgg ttttccacgt ggg 23
<210> 11
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 11
ggggtcagct cacccagcat ggg 23
<210> 12
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 12
ggaagactac aggagggtcc agg 23
<210> 13
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 13
ccataggaac tctgtgcttc ggg 23
<210> 14
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 14
agcagagaag gacccatgct ggg 23
<210> 15
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 15
ccagctaatc aatgtagatg ggg 23
<210> 16
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 16
caggagggtc caggttccat agg 23
<210> 17
<211> 37
<212> DNA
<213> 人工序列(artificial sequence)
<400> 17
atcggcggcc gcaaggtggt cgaaggaagg gagagag 37
<210> 18
<211> 41
<212> DNA
<213> 人工序列(artificial sequence)
<400> 18
gctaggatcc agtactgttt ggcgcggctt gagtttcaca a 41
<210> 19
<211> 35
<212> DNA
<213> 人工序列(artificial sequence)
<400> 19
atgcgtcgac ctgcggcgca ggcgggtttc tagtc 35
<210> 20
<211> 35
<212> DNA
<213> 人工序列(artificial sequence)
<400> 20
actgagatct cgtgggaagc agagaaggac ccatg 35
<210> 21
<211> 35
<212> DNA
<213> 人工序列(artificial sequence)
<400> 21
atcgctcgag tggaaaacca gccttccact cccag 35
<210> 22
<211> 35
<212> DNA
<213> 人工序列(artificial sequence)
<400> 22
atgcgaattc agtctcccgc acacaactgt caaag 35
<210> 23
<211> 26
<212> DNA
<213> 人工序列(artificial sequence)
<400> 23
ggtaaaggaa acccaaacgc gagact 26
<210> 24
<211> 26
<212> DNA
<213> 人工序列(artificial sequence)
<400> 24
cgtgctagat cgactgctag agtgac 26
<210> 25
<211> 27
<212> DNA
<213> 人工序列(artificial sequence)
<400> 25
gacgcctaga ttgtgctact ctcagct 27
<210> 26
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 26
tgttagggca gaaagaggca ccatc 25
<210> 27
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 27
gctgaggaga aaggaaggag aaatc 25
<210> 28
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 28
gggtttcgga gggtgtataa ttagc 25
<210> 29
<211> 45
<212> DNA
<213> 人工序列(artificial sequence)
<400> 29
gcatcaagct tggtaccgat gctagccttg tgcagcatgg aaggc 45
<210> 30
<211> 45
<212> DNA
<213> 人工序列(artificial sequence)
<400> 30
acttaatcgt ggaggatgat cggctagctg taagctcgca caagc 45
<210> 31
<211> 45
<212> DNA
<213> 人工序列(artificial sequence)
<400> 31
gcatcaagct tggtaccgat cgagaagggc gttcaagtaa tggct 45
<210> 32
<211> 45
<212> DNA
<213> 人工序列(artificial sequence)
<400> 32
acttaatcgt ggaggatgat ttgatgctgc cagtctcgta gtacc 45
Claims (7)
1.一种Pax2条件性基因敲除小鼠模型的构建方法,其特征在于,包括以下步骤:(1)以小鼠基因组DNA为模板,分别克隆小鼠Pax2基因的LR、A和RR片段,依次将所述LR、A和RR片段连接至LScKO-2G载体,得特异性打靶载体;克隆所述LR片段的引物包括Pax2-LR-F和Pax2-LR-R,其中所述Pax2-LR-F的核苷酸序列如SEQ ID NO.17所示,所述Pax2-LR-R的核苷酸序列如SEQ ID NO.18所示;克隆所述A片段的引物包括Pax2-A-F和Pax2-A-R,所述Pax2-A-F的核苷酸序列如SEQ ID NO.19所示,所述Pax2-A-R的核苷酸序列如SEQ ID NO.20所示;克隆所述RR片段的引物包括Pax2-RR-F和Pax2-RR-R,所述Pax2-RR-F的核苷酸序列如SEQ IDNO.21所述,所述Pax2-RR-R的核苷酸序列如SEQ ID NO.22所示;
(2)将靶向小鼠Pax2基因的sgRNA合成oligos,连接入pUC载体,得Cas9/sgRNA质粒;所述sgRNA的5’Guide序列如SEQ IDNO.5所示,且所述sgRNA的3’Guide序列如SEQ ID NO.10所示;
(3)将Cas9/sgRNA质粒和所述特异性打靶载体显微注射到小鼠受精卵中,出生后得F0代小鼠;
(4)筛选F0代小鼠中基因重组正确的个体与野生型小鼠交配得到F1代小鼠;
(5)筛选所述F1代小鼠中基因正确表达的杂合子小鼠与组织特异性的Cre小鼠交配,得所述Pax2条件性基因敲除小鼠模型;
步骤(1)和(2)之间不存在时间上的先后关系。
2.根据权利要求1所述构建方法,其特征在于,步骤(1)中扩增所述LR、A和RR片段的PCR程序,均为:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
3.权利要求1所述构建方法,其特征在于,步骤(1)所述连接包括依次将LR片段连接至NotI和BamHI酶切位点之间,将A片段连接至SalI和BglII酶切位点之间,将RR片段连接至XhoI和EcoRI酶切位点之间。
4.权利要求1所述构建方法,其特征在于,步骤(4)所述筛选包括利用两对引物进行PCR,其中一对包括Pax2-L-GT-F和cKO-5'-DO-F;另一对包括cKO-3'-DO-R和Pax2-R-GT-R;
所述Pax2-L-GT-F的核苷酸序列如SEQ ID NO.23所示,所述cKO-5'-DO-F的核苷酸序列如SEQ ID NO.24所示;
所述cKO-3'-DO-R的核苷酸序列如SEQ ID NO.25所示,所述Pax2-R-GT-R的核苷酸序列如SEQ ID NO.26所示。
5.根据权利要求1所述构建方法,其特征在于,步骤(5)所述筛选包括利用两对引物进行PCR,其中一对引物包括Pax2-L-GT-F2和cKO-5'-DO-F;另一对引物包括cKO-3'-DO-R和Pax2-R-GT-R1;所述Pax2-L-GT-F2的核苷酸序列如SEQ ID NO.27所示,所述Pax2-R-GT-R1的核苷酸序列如SEQ ID NO.28所示。
6.根据权利要求4或5所述构建方法,其特征在于,步骤(4)和步骤(5)所述筛选时,PCR扩增的程序均包括:94℃预变性2min;98℃变性10s,67℃退火30s,68℃延伸1kb/min,每个循环退火温度降低0.7℃,共15个循环;98℃变性10s,57℃退火30s,68℃延伸1kb/min,25个循环;68℃延伸10min。
7.利用权利要求1或6任一项所述构建方法构建得到的Pax2条件性基因敲除小鼠模型在构建全身性基因敲除小鼠模型中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110381604.5A CN112980846B (zh) | 2021-04-09 | 2021-04-09 | 一种Pax2条件性基因敲除小鼠模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110381604.5A CN112980846B (zh) | 2021-04-09 | 2021-04-09 | 一种Pax2条件性基因敲除小鼠模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112980846A CN112980846A (zh) | 2021-06-18 |
CN112980846B true CN112980846B (zh) | 2023-05-02 |
Family
ID=76339618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110381604.5A Active CN112980846B (zh) | 2021-04-09 | 2021-04-09 | 一种Pax2条件性基因敲除小鼠模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112980846B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114150023B (zh) * | 2021-09-15 | 2023-07-04 | 中南大学湘雅医院 | 内皮细胞特异性pfn1基因敲除小鼠模型的构建方法 |
CN114410630B (zh) * | 2022-03-21 | 2023-04-25 | 云南大学 | 一种tbc1d8b基因敲除小鼠动物模型的构建方法及其应用 |
CN114592011B (zh) * | 2022-05-10 | 2022-08-05 | 广东药康生物科技有限公司 | 一种ptdss2条件性基因敲除小鼠模型的构建方法 |
CN117568398B (zh) * | 2023-09-19 | 2024-06-04 | 新乡医学院 | 一种PGC-1α基因敲除小鼠构建心律失常动物模型的方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110438160A (zh) * | 2019-07-18 | 2019-11-12 | 浙江大学 | 一种Cd2ap基因敲除动物的构建方法及应用 |
CN111748582A (zh) * | 2020-07-06 | 2020-10-09 | 青岛大学附属医院 | 一种条件敲除Foxp3基因鼠的构建方法 |
-
2021
- 2021-04-09 CN CN202110381604.5A patent/CN112980846B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110438160A (zh) * | 2019-07-18 | 2019-11-12 | 浙江大学 | 一种Cd2ap基因敲除动物的构建方法及应用 |
CN111748582A (zh) * | 2020-07-06 | 2020-10-09 | 青岛大学附属医院 | 一种条件敲除Foxp3基因鼠的构建方法 |
Non-Patent Citations (3)
Title |
---|
《Generation of Pax2‐Cre mice by modification of a Pax2 bacterial artificial chromosome》;T Ohyama等;《Genesis》;20041231;第38卷;第195-199页 * |
《Increased repetitive self-grooming occurs in Pax2 mutant mice generated using CRISPR/Cas9》;Hongen Wei等;《Behavioural Brain Research》;20200901;第393卷;第2页右栏 * |
Hongen Wei等.《Increased repetitive self-grooming occurs in Pax2 mutant mice generated using CRISPR/Cas9》.《Behavioural Brain Research》.2020,第393卷第1-7页. * |
Also Published As
Publication number | Publication date |
---|---|
CN112980846A (zh) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112980846B (zh) | 一种Pax2条件性基因敲除小鼠模型的构建方法 | |
Xu et al. | Generation of targeted mutant rice using a CRISPR‐Cpf1 system | |
EP3476865B1 (en) | Method for constructing pd-1 gene-modified humanized animal model and use thereof | |
Ye et al. | Robust CRISPR/Cas9 mediated genome editing and its application in manipulating plant height in the first generation of hexaploid Ma bamboo (Dendrocalamus latiflorus Munro) | |
CN110551759B (zh) | 一种提高转基因细胞重组效率的组合物及方法 | |
Nishimura et al. | Isolation of a rice regeneration quantitative trait loci gene and its application to transformation systems | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
WO2006025879A3 (en) | Novel polynucleotides related to oligonucleotide arrays to monitor gene expression | |
CN110438160B (zh) | 一种Cd2ap基因敲除动物的构建方法及应用 | |
WO2020077930A1 (zh) | 一种应用Cas9技术制备CKO/KI动物模型的方法 | |
CN111748582A (zh) | 一种条件敲除Foxp3基因鼠的构建方法 | |
CN110541002A (zh) | 一种利用CRISPR/Cas9技术构建斑马鱼asap1b基因敲除突变体的方法 | |
Kibe et al. | The DNMT3A PWWP domain is essential for the normal DNA methylation landscape in mouse somatic cells and oocytes | |
CN110592135A (zh) | 一种CRISPR/Cas9编辑水稻香味基因Badh2的方法 | |
CN111206054B (zh) | 一种利用CRISPR-Cas9条件性敲除肝脏HO-1基因动物模型的构建方法 | |
CN113801893A (zh) | 一种Psme3条件性基因敲除小鼠模型的构建方法及其应用 | |
CN113897369A (zh) | KRT10定点基因敲入P2A-CrePR1-T2A-tdTomato小鼠模型的构建及应用 | |
CN112481301B (zh) | Stap2基因点突变敲入模式小鼠的打靶载体和构建方法 | |
Wang et al. | Engineering bacterial blight-resistant plants through CRISPR/Cas9-targeted editing of the MeSWEET10a promoter in cassava | |
Dalla Costa et al. | Elaboration of a reliable strategy based on real-time PCR to characterize genetically modified plantlets and to evaluate the efficiency of a marker gene removal in grape (Vitis spp.) | |
CN112063654B (zh) | 一种点突变血小板无力症小鼠模型的构建方法 | |
CN109694885B (zh) | 基于CRISPR/Cas9技术制备PI3Kγ全身敲除模式小鼠方法及其应用和试剂盒 | |
CN113564204B (zh) | 细胞色素p450酶人源化大鼠模型及其构建方法和应用 | |
CN110157704B (zh) | 一种抗小鼠肝炎病毒的小鼠及其制备方法 | |
CN114410630B (zh) | 一种tbc1d8b基因敲除小鼠动物模型的构建方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |